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has provided to increased our ability to delivery radiation doses
that conform more to the tumour volume avoiding geometrical
uncertainties. The variations in the position of the target vol-
ume may occur daily during treatment. in the treatment of
prostate cancer. The obtainable clinical benefits through the
use of highly conformal treatments cannot be gotten if the
internal target volume motion are quantified and if necessary
compensated. Since, radiation dose escalation in prostate can-
cer may lead to an increase of the disease control, the Image
Guided Radiation Therapy (IGRT) may be of great utility in to
define target volume, the organ motion and the in to decrease
the geographical miss. The assessment of IGRT may add infor-
mation in the treatment position and real time monitoring dur-
ing treatment delivery.
The IGRT allows to immediately visualise before the adminis-
tration of the fraction of dose the anatomy of the patient to the
purpose to subsequently conform the dose to the volume target.
For this reason, considerable research have been made on
the methods of using three-dimensional images of patient on
the planning, delivery and verify of radiotherapy treatment.
The IGRT includes various technologies as ultrasound,
implanted fiducial markers, in-room diagnostic CT or kilovoltage
X-rays, megavoltage cone-beam computed tomography (MV
CBCT) or kilovoltage cone beam computed tomography (kV
CBCT). In conclusion the use of the new imaging techniques
he will be able in a next future to improve the results in the care
of the prostate cancer and the relationship efficacy and toxicity
in the radiotherapy treatment.
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Despite the effectiveness of initial hormonal therapy, meta-
static cancer prostate is an incurable disease, with median sur-
vival of 6–9 months after development of androgen insensitivity.
The combination of mitoxantrone and prednisone has been
approved for use in patients with hormone-refractory prostate
cancer. The combination of docetaxel and prednisone in two
study recently have demonstrated for the first time a chemother-
apy could extend survival in the patients.
The purpose of the our study was to define the efficacy and
safety of scheme therapeutic, repeat every 28 d, in cancer pros-
tate hormone-refractory.
The treatment includes:
 Megestrol acetate 160 mg/die per os;
 Docetaxel 40 mg/m2 e.v. days 1,16;
 Novantrone 8 mg/m2 e.v (infusion continual from 2 day to
15 day);
 Prednisone 5 mg os die alternated.
Biological efficacy was defined as a decline of >50% from base-
line levels PSA.
We treated 23 patients,from February 2006 to february
2008,with metastatic prostate cancer, median 72 years, range
55–74 years. After 2 months the patients with tumor response
or stable received 2,4, . . . another months of chemotherapy until
disease progression or toxicity or patient’s refusal, nevertheless
forever <13 cycle.
The results are very encouraging: decrease in serum
PSAP 50% in 16 patients/23, increase of hemoglobin in 12
patients/23,improvement symptomatic in 17 patients/23.
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